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Background: Intensive care unit (ICU)-acquired delirium is frequent and associated 
with poor short- and long-term outcomes for patients in ICUs. It therefore consti-
tutes a major healthcare problem. Despite limited evidence, haloperidol is the most 
frequently used pharmacological intervention against ICU-acquired delirium.
Agents intervening against Delirium in the ICU (AID-ICU) is an international, multi-
centre, randomised, blinded, placebo-controlled trial investigates benefits and harms 
of treatment with haloperidol in patients with ICU-acquired delirium. The current 
pre-planned one-year follow-up study of the AID-ICU trial population aims to ex-
plore the effects of haloperidol on one-year mortality and health related quality of 
life (HRQoL).
Methods : The AID-ICU trial will include 1000 participants. One-year mortality will 
be obtained from the trial sites; we will validate the vital status of Danish partici-
pants using the Danish National Health Data Registers. Mortality will be analysed by 
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1  | BACKGROUND
Delirium is an acute brain dysfunction accompanying underlying 
somatic illness and characterized by marked and fluctuating dis-
turbances in consciousness and in cognition. Clinical hallmarks in-
clude memory deficits, disorientation, perceptual disturbances and 
inattention.1-3
Delirium is a common clinical condition occurring during both 
acute illness and hospitalization in general.4 The condition is particu-
larly prevalent in patients with critical illness treated at the intensive 
care unit (ICU), where prevalence of ICU-acquired delirium ranges 
from 20% to 80%.1,5
Intensive care unit-acquired delirium is associated with significant 
adverse short- and long-term outcomes. In the short term, predomi-
nant associations of delirium include increased risk of prolonged me-
chanical ventilation and longer hospital stay, while frequent long-term 
associated outcomes include functional disability in activities of daily 
living, as well as cognitive impairments such as memory deficits and 
poor concentration.6,7 Notably, cognitive impairments may be per-
sistent and reported years after the critical illness with delirium.8,9
Compared to the general population, ICU-survivors have reported 
a lower health-related quality of life (HRQoL) at 1 year after critical 
illness.10 Moreover, ICU-survivors with delirium during the ICU ad-
mission have reported a higher prevalence of cognitive problems as 
compared to all ICU survivors.9,11 Recent studies have indicated an 
association between ICU-acquired delirium and increased mortality, 
whereas previous studies did not confirm this finding.6,7,11,12
Despite limited evidence, treatment of ICU-acquired delirium 
with haloperidol is currently the most frequently used pharmaco-
logical intervention.13 The “Agents Intervening against Delirium in 
the Intensive Care Unit” (AID-ICU) trial, is a multicentre random-
ized blinded and placebo-controlled trial (RCT) that aims to assess 
benefits and harms of haloperidol for treatment of delirium in adult 
critically ill patients admitted to the ICU.14 The trial is ongoing and is 
expected to complete inclusions in 2021.
As concluded in a recent systematic review, long-term conse-
quences of delirium are evident.15 Therefore it is imperative to in-
vestigate the impact of haloperidol, the most widely used treatment 
of this potentially disabling condition, on both short-and long-term 
outcomes.15 This protocol article describes the long-term follow-up 
of such patients treated with haloperidol.
1.1 | Aim
To assess the effect of haloperidol treatment on mortality and 
health-related quality of life in ICU patients with delirium 1 year 
after randomization into the AID-ICU trial.
1.2 | Hypothesis
We expect that the allocation to haloperidol vs placebo has an im-
pact on mortality and the duration of delirium in patients suffering 
ICU-acquired delirium and hypothesize that haloperidol will reduce 
mortality and increase quality of life 1 year after discharge.
2  | MATERIAL S AND METHODS
2.1 | Ethical considerations
Ethical approval for the AID-ICU trial including the 1-year follow-up 
study, has been obtained from the Danish Medicines Agency (EudraCT 
no. 2017-003829-15), the National Committee on Health Research 
Ethics (SJ-646) and the Danish Data Protection Agency (REG-169-
2017). After achievement of approvals from national authorities and ac-
cording to national law, inclusion at international sites has been initiated. 
Informed consent given to the AID-ICU trial also include approval for 
this 1-year follow-up study. Further details can be obtained in the pro-
tocol of the AID-ICU trial which also includes a description of protection 
of data.14 The trial is registered at Clinicaltrials.gov: NCT03392376.
2.2 | AID-ICU trial
Adult ICU patients with delirium confirmed by either the Confusion 
Assessment Method for the Intensive Care Unit (CAM-ICU) or the 
Cox-regression and visualized by Kaplan-Meier curves tested for significance using 
the log-rank test. We will obtain HRQoL data using the EQ-5D instrument. HRQoL 
analysis will be performed using a general linear model adjusted for stratification vari-
ables. Deceased participants will be designated the worst possible value.
Results: We expect to publish results of this study in 2022.
Conclusion: We expect that this one-year follow-up study of participants with ICU-
acquired delirium allocated to haloperidol vs. placebo will provide important informa-
tion on the long-term consequences of delirium including the effects of haloperidol. 
We expect that our results will improve the care of this vulnerable patient group.
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Intensive Care Delirium Screening Checklist (ICDSC), are screened 
by trained nurses or doctors for enrolment into the AID-ICU trial. 
Enrolled participants are randomized 1:1 to intravenous haloperidol 
2.5 mg or placebo (isotonic saline), three times daily and additional 
as-needed doses of 2.5 mg haloperidol or placebo up to a total daily 
dose of 20 mg haloperidol or placebo. An escape protocol is available 
in case of uncontrollable delirium or patient discomfort. Open label 
antipsychotic treatment is not allowed. The primary outcome of the 
AID-ICU trial is days alive out of the hospital within 90 days post-ran-
domization. More details about the AID-ICU trial protocol have been 
published elsewhere (www.cric.nu/aid-icu-trial -docum ents/).14,16
2.3 | Study population
The study population for this 1-year follow-up consists of partici-
pants randomized in the AID-ICU trial. See Figure 1
2.4 | Outcomes measures
2.4.1 | Primary outcomes
• Difference in mortality 1 year after randomization between par-
ticipants in the haloperidol group and the placebo group
• Difference in EQ-5D 1 year after randomization between partici-
pants in the haloperidol group and the placebo group.
2.4.2 | Secondary outcomes
• Difference in EQ-5D 1 year after randomization between the sur-
vivors only in the haloperidol group and the placebo group
• Differences in the single sub-domains of the EQ-5D 1 year after 
randomization between survivors in the haloperidol group and 
the placebo group: mobility, self-care, usual activities, pain/dis-
comfort, anxiety/depression and overall health rated by EQ-VAS 
(visual analog scale).
2.5 | Data collection
2.5.1 | One-year mortality
Survival status of the participants will be obtained by patient records 
and entered into the database by the individual site or national in-
vestigators 1 year after randomization. For the Danish sites vital sta-
tus will be validated by information from the Danish National Patient 
Registry and the Danish Civil Registration System.
2.5.2 | EQ-5D
The five-level EQ-5D tool includes EQ-VAS and EQ-5D-5L and 
is a validated self-reported questionnaire recommended for use 
in ICU settings.16,17 The EQ-VAS is a scale ranging from 0 to 100 
F I G U R E  1   CONSORT flow diagram for the AID-ICU trial 1-yr follow-up [Colour figure can be viewed at wileyonlinelibrary.com]
1522  |     MORTENSEN ET al.
where participants indicate their overall health status on that day 
and where 100 is rated as the best possible health.17 The ques-
tionnaire EQ-5D measures five health problems according to a 
five-dimensional classification: mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression, where the participants 
are asked to grade their level of function or disability. Each of the 
five dimensions are ranked on five levels of perceived problems 
ranging from 1 to 5; where 1 = no problems, 2 = slight problems, 
3 = moderate problems, 4 = severe problems and 5 = extreme 
problems. The participant will be asked to rate their problems for 
each of the five dimensions.
The response of each dimension provides a simple descriptive 
profile (a digit-code (1-5)), which is used to generate a unique health 
state. The health state cannot be summarized since each number 
represent the five severity levels of each dimension and has no arith-
metic properties.18
In countries where there is no current calculation norm for 
translation of health state in EQ-5D-5L, but only EQ-5D-3L, we 
will use EQ-5D-5L crosswalk index to ‘convert’ the EQ-5D-3L to 
EQ-5D-5L.19
2.5.3 | Collection of EQ-5D data
Surviving participants in the AID-ICU trial will be contacted 1 year 
after randomization by the national investigators or their del-
egates. In case of no response to phone calls, a mail survey will 
be dispatched. Collection of EQ-5D data outside of Denmark will 
be obtained by the national or site investigators and handled ac-
cording to local practice. All data will be registered in the elec-
tronic case report file (eCRF) by investigators blinded to the trial 
intervention.
3  | STATISTIC AL ANALYSES
All primary analyses will be performed in the intention-to-treat pop-
ulation of the AID-ICU trial population. There is no specific sample 
size calculation for this follow-up study.
Demographic data and patient characteristics including baseline 
data obtained at randomization will analysed by descriptive sta-
tistics and will be presented as mean and standard deviation (SD), 
median and interquartile range (IQR), or proportions with percent-
ages where relevant. For further information, see the AID-ICU trial 
protocol.14,20
3.1 | Choice of statistical method
3.1.1 | One-year mortality
On assessing the landmark mortality at 1 year (every patient in the 
AID-ICU trial will be followed up 1 year from randomization), data will 
be analysed using logistic regression adjusted for stratification vari-
ables (site and delirium motor subtypes (hypoactive or hyperactive)at 
randomization) for differences in the binary outcome (alive/dead) and 
presented as odds ratios. Furthermore, survival data will be analysed 
by Cox-regression and visualized by a Kaplan-Meier curve. Also, for 
1-year mortality including, overall mortality and mortality between the 
two groups additional analyses of the stratification variables site and 
delirium motor subtypes (hypoactive or hyperactive) and the baseline 
characteristics, site, sex, age (<69 year and ≥ 69 year) and Simplified 
Mortality Score in the ICU (SMS-ICU) (<25-≥25) will be applied.14
3.1.2 | EQ-5D
For the primary analysis of EQ-5D will EQ-VAS which is the respond-
ent's self-rated health be used for all participants. Differences in 
means of EQ-VAS are compared between the two groups and assum-
ing that the distribution of EQ-VAS or log-transformed data comes 
close to a normal distribution, the analysis of choice will be multiple 
linear regression adjusted for stratification variables site and delir-
ium motor subtype. However, if the distribution of EQ-VAS is clearly 
non-normal, we will use the Van Elteren test to explore differences 
of medians between the two groups, after adjusting for stratification 
variables site and delirium motor subtype. Secondary analyses of the 
single sub-domains of EQ-5D (mobility, self-care, usual activities, pain/
discomfort and anxiety/depression) will also be performed with a gen-
eralized linear model (GLM) or Van Elteren adjusted for the stratifi-
cation variables site and delirium motor subtype. As a supplement to 
the primary analysis, an analysis adjusting for both the stratification 
variables site and delirium motor subtypes (hypoactive or hyperactive) 
and the pre-defined covariates of sex, age (<69 year and ≥ 69 year) and 
SMS-ICU (<25-≥ 25) will be applied.
3.1.3 | Evaluation of treatment despite 
1-year mortality
High 1-year mortality rate challenges the statistical evaluation of the 
treatment effects in this population if not taken into consideration.21 
To account for the expected high mortality, participants dying within 
12 months after randomization are ‘truncated due to death’, mean-
ing assignment of the worst possible value; the value of zero.21 With 
respect to the intention-to-treat principle, we will compare this highly 
non-normal distributed outcome between treatment groups using a 
novel method described by Jensen et al22 In addition, the analysis will 
be supplemented with a per-protocol analysis within the population of 
the 1-year survivors. See Figure 2 for an overview of statistical analysis.
3.1.4 | Significance
A two-sided P< .05 will be considered statistically significant and if data 
are normally distributed (or nearly), we will provide 95% confidence 
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intervals between means. For non-normally distributed data, 95% con-
fidence intervals between medians will be estimated by bootstrapping.
3.2 | Handling missing values
EQ-5D data may be missing in participants who are alive 1 year after 
randomization (non-responders or migrated participants). If data of the 
EQ-5D questionnaires are missing for less than 5% of the participants or 
data are missing completely at random (MCAR),that is, negative Little's 
test (P > .05), we will not impute missing data. If data are missing for 
outcomes and adjusted covariates in more than 5% of the participants, 
assuming data missing at random (MAR), we will impute data using multi-
ple imputation (MI) generating 50 imputed data sets. If MI is considered 
necessary, aggregated analysis of the imputed datasets is calculated. 
However, assuming data are not missing at random (MNAR), we will 
conduct analyses in best-worse and worse-best scenarios imputing data 
from missing response from survivors, using the mean plus/minus 1 SD 
of the EQ-5D in participants with complete data.
4  | DISCUSSION
This protocol article describes the 1 year follow-up study on mortality 
and health-related quality of life for participants in the AID-ICU trial.
4.1 | One-year mortality
While delirium has been linked to long-term mortality, limited evi-
dence exists for the impact of delirium treatment with haloperidol 
on long-term mortality.12 Three placebo controlled RCTs have ex-
plored the effect of haloperidol on short-term mortality (from 28 to 
90 days) and found no differences in mortality between the treat-
ment groups.23-25 None of the three RCTs have reported on 1-year 
mortality.
4.2 | Long-term HRQoL
Two recently published systematic reviews found no studies explor-
ing explicitly if haloperidol treatment has an impact on long-term 
HRQoL. Few studies have explored the impact of ICU-acquired de-
lirium on HRQoL in ICU survivors after discharge.9,11 In these stud-
ies, no difference in HRQoL was found between the delirious and 
the non-delirious participants when adjusting for confounders.9,11 
Both studies were prospective, but one of the studies9 did not re-
port on non-responders nor their characteristics, rendering the re-
sults subject to attrition bias therefore compromising the internal 
and external validity.9,11 In order to ensure high validity, the AID-ICU 
trial will provide detailed description of all the participants’ base-
line information and include deceased participants into the analyses. 
F I G U R E  2   Analysis diagram for the 
AID-ICU 1-yr follow-up [Colour figure can 
be viewed at wileyonlinelibrary.com]
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Hereby, we believe, that it is the best possible way to explore a true 
difference in outcomes caused by the intervention.
We will perform a secondary analysis of EQ-5D data, including 
only the survivors for further exploration of the treatment effect be-
tween the intervention and control group. Measuring HRQoL of ICU 
survivors is complex and difficult because of the heterogeneity of 
the patient population and the different trajectories of illness before 
and after critical illness. However EQ-5D is characterized by being 
brief, easy-to-use and flexible in different settings and has been 
recommended for use in ICU settings.26,27 Furthermore, applying a 
simple short generic instrument like EQ-5D is suitable for partici-
pants that might be challenged with cognitive impairment. In spite of 
its brevity, EQ-5D still encompasses a global description of HRQoL 
which includes a medical interpretation and an interpretation of the 
social, emotional and physical function.28
4.3 | Strengths
The AID-ICU trial is a large multicentre RCT designed to provide 
high-quality data with low risk of bias and high external validity. The 
AID-ICU trial is the largest treatment study on haloperidol and will 
add evidence concerning the benefits and harms of haloperidol for 
treatment of delirium among critically ill patients. This protocol ar-
ticle includes a statistical analysis plan for 1-year follow-up and has 
been drafted to measure the effect of the intervention on HRQoL 
and death. Secondly, it also helps to explore difference in HRQoL 
between the survivors in the two interventional groups.
4.4 | Limitations
To explore a complex association between haloperidol treatment of 
ICU-acquired delirium and mortality 1 year later might be challenged 
by attrition bias due to loss to follow-up. ICU survivors are a vulnerable 
patient cohort that struggles with both physical and psychological dis-
abilities and follow-up in such population has previously shown to be 
challenging.29,30 A major concern in longitudinal studies is, that with 
a long follow-up period, the risk of attrition and loss to follow-up will 
increase. If too many participants are lost to follow-up there is a risk of 
selection bias if missing data are not taken into consideration.31 This 
might compromise the study's ability to fully describe the diversity of 
the study population. If data are missing, that is, lost to follow-up by 
more than 5%, we will handle missing data as previously described.
4.5 | Perspective
Critically ill patients admitted to the ICU are at high risk of developing 
delirium, and currently, there is limited evidence of the effect of halo-
peridol treatment on both short- and long-term outcomes. This fol-
low-up study of the AID-ICU trial will provide important information 
about the benefits and harms of haloperidol treatment on long-term 
mortality and HRQoL. The cohort consists of a representative sample 
of ICU patients with onset of delirium at different times during the ICU 
admission, and thereby has a high degree of generalizability.
4.6 | Trial status
The AID-ICU trial began recruitment in June 2018. Currently 553 of 
1000 planned participants have been enrolled (July 6th, 2020). We 
expect the enrolment target to be met by 2021. The data collection 
of the present follow-up study was initiated in June 2019.
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